N
XFOR icon

Nuveen’s X4 Pharmaceuticals XFOR Stock Holding History

Nuveen’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,625
Closed -$334K – 3346
2024
Q3 		$334K Hold
16,625
– – ﹤0.01% 3125
2024
Q2 		$289K Buy
16,625
+2,021
+14% +$66.1K ﹤0.01% 3160
2024
Q1 		$609K Hold
14,604
– – ﹤0.01% 2909
2023
Q4 		$367K Hold
14,604
– – ﹤0.01% 3099
2023
Q3 		$478K Hold
14,604
– – ﹤0.01% 2857
2023
Q2 		$850K Buy
+14,604
New +$750K ﹤0.01% 2724
2021
Q2 		– Sell
-2,670
Closed -$689K – 3552
2021
Q1 		$689K Sell
2,670
-138
-5% -$36.3K ﹤0.01% 3012
2020
Q4 		$541K Buy
2,808
+38
+1% +$7.46K ﹤0.01% 3026
2020
Q3 		$562K Buy
2,770
+14
+0.5% +$3.36K ﹤0.01% 2915
2020
Q2 		$771K Buy
2,756
+1,294
+89% +$354K ﹤0.01% 2731
2020
Q1 		$439K Buy
1,462
+389
+36% +$110K ﹤0.01% 2813
2019
Q4 		$344K Hold
1,073
– – ﹤0.01% 2978
2019
Q3 		$409K Buy
1,073
+679
+172% +$269K ﹤0.01% 2999
2019
Q2 		$177K Buy
+394
New +$200K ﹤0.01% 3191

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen's XFOR Position: Q4 2024 in Review

Nuveen sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 16,625 shares — an estimated $334K sold.

Nuveen first reported a position in XFOR in Q2 2019 and held it in 14 quarters. The position peaked at $850K in Q2 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Nuveen reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Nuveen sold 16,625 X4 Pharmaceuticals shares in Q4 2024, an estimated $334K.
  • Nuveen first reported a position in X4 Pharmaceuticals in Q2 2019 and held it in 14 quarters.
  • Nuveen's X4 Pharmaceuticals position peaked at $850K in Q2 2023.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Nuveen's 13F filing for Q4 2024, filed 14 Feb 2025.